

116TH CONGRESS  
1ST SESSION

# H. R. 3044

To establish the Medical Device Sterilization Challenge, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

MAY 30, 2019

Mr. LIPINSKI introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Science, Space, and Technology, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To establish the Medical Device Sterilization Challenge, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Medical Device Steri-  
5 lization Challenge Act of 2019”.

6 **SEC. 2. MEDICAL DEVICE STERILIZATION CHALLENGES.**

7 (a) **AUTHORITY.**—Not later than 180 days after the  
8 date of enactment of this Act, the Commissioner of Food  
9 and Drugs shall establish a program to be known as

1 “Medical Device Sterilization Challenge” for carrying out  
2 prize competitions described in this section under section  
3 24 of the Stevenson-Wydler Technology Innovation Act of  
4 1980 (15 U.S.C. 3719) relating to sterilization of medical  
5 devices.

6 (b) PRIZE COMPETITIONS.—In carrying out the pro-  
7 gram, the Director shall provide for prize competitions,  
8 including at least one prize competition to seek solutions  
9 with respect to each of the following goals:

10 (1) Reduction of the human health hazards as-  
11 sociated with ethylene oxide sterilization, including  
12 through reduction of—

13 (A) the exposure to workers in such facili-  
14 ties; and

15 (B) environmental emissions of ethylene  
16 oxide.

17 (2) Reduction of the amount of time required to  
18 effectively sterilize devices by a factor of 2 or more  
19 to sterilize the same type and number of devices over  
20 commonly-used ethylene oxide technology without a  
21 proportional increase in cost.

22 (3) Achievement of rapid implementation of  
23 new sterilization agents or methods that minimize  
24 conversion costs without decreasing facility through-  
25 put.

1           (4) Provision of new or improved approaches to  
2 measuring, monitoring, and controlling ethylene  
3 oxide emissions, including detection at very low lev-  
4 els.

5           (5) Analysis of public health risks of emissions  
6 from currently-available data with respect to emis-  
7 sions of public health or provision of—

8                   (A) new or improved tools that use data to  
9 better model emissions over time at the regional  
10 or local scale; or

11                   (B) actionable information on the health  
12 and environmental impacts of ethylene oxide  
13 sterilization to government, industry, and mem-  
14 bers of the public.

15           (6) Enabling of minimally disruptive conversion  
16 of exiting device sterilization facilities that use ethyl-  
17 ene oxide to convert to less-toxic methods of steri-  
18 lization.

19           (c) PRIZE COMMITTEES.—

20                   (1) IN GENERAL.—The Director of the Center  
21 for Devices and Radiological Health shall assemble  
22 a prize committee with respect to each prize com-  
23 petition that shall define the scope and detail of, and  
24 provide the requirements for, the prize competitions

1 under this section. Such committee shall be com-  
2 posed of—

3 (A) members from the Federal agency, de-  
4 partment, or office that most appropriately cor-  
5 responds with the topic of the prize competi-  
6 tion, including—

7 (i) with respect to a prize competition  
8 under subsection (b)(1), the Director or  
9 designee of the National Institutes of  
10 Health;

11 (ii) with respect to a prize competition  
12 under paragraphs (2), (3), (5), and (6) of  
13 subsection (b), the Director or designee of  
14 the National Science Foundation; and

15 (iii) with respect to a prize competi-  
16 tion under paragraphs (4) and (5) of sub-  
17 section (b), the Administrator or designee  
18 of the Environmental Protection Agency;  
19 and

20 (B) representatives of any other entities,  
21 as determined appropriate by the Director, in-  
22 cluding State and local governments and the  
23 private sector.

24 (2) DEFINING TOPIC AREAS.—The prize com-  
25 mittee may modify and define the scope of the prize

1 areas described under subsection (b), so long as such  
2 modification is in accordance with descriptions in  
3 such subsection.

4 (3) INCENTIVE FOR PRIZE COMPETITION.—The  
5 prize committee for each prize competition shall de-  
6 termine the incentive for such prize competition. In  
7 determining the incentive, the committee may con-  
8 sider—

9 (A) a cash prize;

10 (B) access to Government facilities, a coop-  
11 erative research and development agreement, or  
12 other method;

13 (C) with respect to for a product of use or  
14 promise to the Federal Government, a commit-  
15 ment by the Federal Government to purchase a  
16 set number of units of a product from at an  
17 agreed-upon price before the product is brought  
18 to market;

19 (D) participation in entrepreneurship men-  
20 toring programs;

21 (E) consultation and mentoring through  
22 the regulatory pathway towards approval for  
23 use; or

24 (F) any other incentive provided for by  
25 law.

1           (4) JUDGING CRITERIA.—The prize committee  
2 for each prize competition shall establish judging cri-  
3 teria for the competition that shall include—

4           (A) potential for the solution to become a  
5 commercial product or service or advance  
6 knowledge to further the public good;

7           (B) consideration of how likely the solution  
8 is to lead to subsequent research, development,  
9 or manufacturing in the United States;

10          (C) the degree to which the solution will  
11 reduce the public health burden created by  
12 ethylene oxide sterilization of medical devices;  
13 and

14          (D) the degree to which the solution will  
15 reduce emissions and the environmental health  
16 burden created by ethylene oxide emissions  
17 from the sterilization of medical devices.

18          (5) CONSIDERATION.—In carrying out this sec-  
19 tion, the committee shall take into consideration the  
20 best practices provided for in the challenges and  
21 prizes toolkit made publicly available on December  
22 15, 2016, by the General Services Administration.

23          (d) ACCEPTANCE OF FUNDS.—In addition to such  
24 sums as may be appropriated or otherwise made available  
25 to the Director to award prizes under this section, the Di-

1 rector may accept funds from other Federal agencies, and  
2 State and local governments to award prizes under this  
3 section.

4 (e) ELIGIBILITY.—Notwithstanding section 24(g)(3)  
5 of the Stevenson-Wydler Technology Innovation Act of  
6 1980 (15 U.S.C. 3719(g)(3)), a group may be eligible for  
7 an award under this section if 1 member of such group  
8 is a citizen or permanent resident of the United States.

9 (f) COMPLETION OF PRIZE COMPETITIONS.—The  
10 prize competitions carried out under this section shall be  
11 completed not later than the date that is 5 years after  
12 the program is established under subsection (a).

13 (g) AUTHORIZATION OF APPROPRIATIONS.—There is  
14 authorized to be appropriated \$20,000,000 to carry out  
15 this section, to remain available until expended.

16 **SEC. 3. AGENCY ACTIVITIES TO SUPPORT NOVEL AND**  
17 **EARLY-STAGE TECHNOLOGY FOR MEDICAL**  
18 **DEVICE STERILIZATION.**

19 (a) NATIONAL SCIENCE FOUNDATION.—During the  
20 5 year period beginning on the date of the enactment of  
21 this Act, the National Science Foundation shall use exist-  
22 ing authority to award grants on a competitive basis to  
23 investigator-initiated research projects that may lead to  
24 the development, implementation, and assessment of novel

1 sterilization methods, including traineeships for those who  
2 perform this research in academic and industrial settings.

3 (b) NATIONAL INSTITUTES OF HEALTH.—The Direc-  
4 tor of the National Institutes of Health shall—

5 (1) support or conduct research on the health  
6 effects of—

7 (A) novel sterilization methods, particu-  
8 larly those methods that are well-suited for ma-  
9 terials for which ethylene oxide is currently the  
10 best available sterilization method, including re-  
11 search on the efficacy of the method on a broad  
12 range of materials commonly used in medical  
13 devices, on individuals who receive medical de-  
14 vices;

15 (B) emissions from such novel sterilization  
16 methods on individuals in the surrounding com-  
17 munities; and

18 (C) ethylene oxide, particularly on the mor-  
19 bidity secondary to occupational or environ-  
20 mental exposure at levels measured near  
21 sources that emit ethylene oxide; and

22 (2) award grants, on a competitive basis, to en-  
23 able institutions to support graduate students and  
24 postdoctoral fellows who perform research on novel

1 sterilization methods in both academic and industry  
2 settings.

3 (c) ENVIRONMENTAL PROTECTION AGENCY.—The  
4 Environmental Protection Agency shall support or conduct  
5 research on how products, processes, and systems used to  
6 produce proposed alternatives to ethylene oxide steriliza-  
7 tion will affect the environment.

8 **SEC. 4. GAO REPORT.**

9 Not later than 10 years after the implementation of  
10 this Act, the Comptroller General of the United States  
11 shall submit to Congress a report on the impact and the  
12 effectiveness of the provisions of this Act at achieving the  
13 goals described in subsection (b).

○